Your browser doesn't support javascript.
loading
Preclinical Models of Neuroendocrine Neoplasia.
Sedlack, Andrew J H; Saleh-Anaraki, Kimia; Kumar, Suresh; Ear, Po Hien; Lines, Kate E; Roper, Nitin; Pacak, Karel; Bergsland, Emily; Quelle, Dawn E; Howe, James R; Pommier, Yves; Del Rivero, Jaydira.
Affiliation
  • Sedlack AJH; National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Saleh-Anaraki K; Medical Scientist Training Program, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
  • Kumar S; National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Ear PH; National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Lines KE; Department of Surgery, University of Iowa, Iowa City, IA 52242, USA.
  • Roper N; Oxford Center for Diabetes, Endocrinology, and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK.
  • Pacak K; National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Bergsland E; Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA.
  • Quelle DE; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
  • Howe JR; Department of Neuroscience and Pharmacology, University of Iowa, Iowa City, IA 52242, USA.
  • Pommier Y; Department of Surgery, University of Iowa, Iowa City, IA 52242, USA.
  • Del Rivero J; National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Cancers (Basel) ; 14(22)2022 Nov 17.
Article in En | MEDLINE | ID: mdl-36428741
Neuroendocrine neoplasia (NENs) are a complex and heterogeneous group of cancers that can arise from neuroendocrine tissues throughout the body and differentiate them from other tumors. Their low incidence and high diversity make many of them orphan conditions characterized by a low incidence and few dedicated clinical trials. Study of the molecular and genetic nature of these diseases is limited in comparison to more common cancers and more dependent on preclinical models, including both in vitro models (such as cell lines and 3D models) and in vivo models (such as patient derived xenografts (PDXs) and genetically-engineered mouse models (GEMMs)). While preclinical models do not fully recapitulate the nature of these cancers in patients, they are useful tools in investigation of the basic biology and early-stage investigation for evaluation of treatments for these cancers. We review available preclinical models for each type of NEN and discuss their history as well as their current use and translation.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Country of publication: